Standard

Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing. / Lukyanov, Sergei A.; Titov, Sergei E.; Kozorezova, Evgeniya S. et al.

In: International Journal of Molecular Sciences, Vol. 25, No. 13, 7090, 07.2024.

Research output: Contribution to journal › Article › peer-review

Harvard

Lukyanov, SA, Titov, SE, Kozorezova, ES, Demenkov, PS, Veryaskina, YA, Korotovskii, DV, Ilyina, TE, Vorobyev, SL, Zhivotov, VA, Bondarev, NS, Sleptsov, IV & Sergiyko, SV 2024, 'Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing', International Journal of Molecular Sciences, vol. 25, no. 13, 7090. https://doi.org/10.3390/ijms25137090

APA

Lukyanov, S. A., Titov, S. E., Kozorezova, E. S., Demenkov, P. S., Veryaskina, Y. A., Korotovskii, D. V., Ilyina, T. E., Vorobyev, S. L., Zhivotov, V. A., Bondarev, N. S., Sleptsov, I. V., & Sergiyko, S. V. (2024). Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing. International Journal of Molecular Sciences, 25(13), [7090]. https://doi.org/10.3390/ijms25137090

Vancouver

Lukyanov SA, Titov SE, Kozorezova ES, Demenkov PS, Veryaskina YA, Korotovskii DV et al. Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing. International Journal of Molecular Sciences. 2024 Jul;25(13):7090. doi: 10.3390/ijms25137090

Author

Lukyanov, Sergei A. ; Titov, Sergei E. ; Kozorezova, Evgeniya S. et al. / Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing. In: International Journal of Molecular Sciences. 2024 ; Vol. 25, No. 13.

BibTeX

@article{a71ce660c9c34bdea54b2845a4eed865,
title = "Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing",
abstract = "Molecular genetic events are among the numerous factors affecting the clinical course of papillary thyroid carcinoma (PTC). Recent studies have demonstrated that aberrant expression of miRNA, as well as different thyroid-related genes, correlate with the aggressive clinical course of PTC and unfavorable treatment outcomes, which opens up new avenues for using them in the personalization of the treatment strategy for patients with PTC. In the present work, our goal was to assess the applicability of molecular markers in the preoperative diagnosis of aggressive variants of papillary thyroid cancer. The molecular genetic profile (expression levels of 34 different markers and BRAF mutations) was studied for 108 cytology specimens collected by fine-needle aspiration biopsy in patients with PTC having different clinical manifestations. Statistically significant differences with adjustment for multiple comparisons (p < 0.0015) for clinically aggressive variants of PTC were obtained for four markers: miRNA-146b, miRNA-221, fibronectin 1 (FN1), and cyclin-dependent kinase inhibitor 2A (CDKN2A) genes. A weak statistical correlation (0.0015 < p < 0.05) was observed for miRNA-31, -375, -551b, -148b, -125b, mtDNA, CITED1, TPO, HMGA2, CLU, NIS, SERPINA1, TFF3, and TMPRSS4. The recurrence risk of papillary thyroid carcinoma can be preoperatively predicted using miRNA-221, FN1, and CDKN2A genes.",
keywords = "CDKN2A, FN1, aggressive variants, miRNA-146b, miRNA-221, papillary thyroid carcinoma, recurrence risk",
author = "Lukyanov, {Sergei A.} and Titov, {Sergei E.} and Kozorezova, {Evgeniya S.} and Demenkov, {Pavel S.} and Veryaskina, {Yulia A.} and Korotovskii, {Denis V.} and Ilyina, {Tatyana E.} and Vorobyev, {Sergey L.} and Zhivotov, {Vladimir A.} and Bondarev, {Nikita S.} and Sleptsov, {Ilya V.} and Sergiyko, {Sergei V.}",
note = "This research was funded by the Russian Science Foundation, grant number 20-14-00074-P.",
year = "2024",
month = jul,
doi = "10.3390/ijms25137090",
language = "English",
volume = "25",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "13",

}

RIS

TY - JOUR

T1 - Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing

AU - Lukyanov, Sergei A.

AU - Titov, Sergei E.

AU - Kozorezova, Evgeniya S.

AU - Demenkov, Pavel S.

AU - Veryaskina, Yulia A.

AU - Korotovskii, Denis V.

AU - Ilyina, Tatyana E.

AU - Vorobyev, Sergey L.

AU - Zhivotov, Vladimir A.

AU - Bondarev, Nikita S.

AU - Sleptsov, Ilya V.

AU - Sergiyko, Sergei V.

N1 - This research was funded by the Russian Science Foundation, grant number 20-14-00074-P.

PY - 2024/7

Y1 - 2024/7

N2 - Molecular genetic events are among the numerous factors affecting the clinical course of papillary thyroid carcinoma (PTC). Recent studies have demonstrated that aberrant expression of miRNA, as well as different thyroid-related genes, correlate with the aggressive clinical course of PTC and unfavorable treatment outcomes, which opens up new avenues for using them in the personalization of the treatment strategy for patients with PTC. In the present work, our goal was to assess the applicability of molecular markers in the preoperative diagnosis of aggressive variants of papillary thyroid cancer. The molecular genetic profile (expression levels of 34 different markers and BRAF mutations) was studied for 108 cytology specimens collected by fine-needle aspiration biopsy in patients with PTC having different clinical manifestations. Statistically significant differences with adjustment for multiple comparisons (p < 0.0015) for clinically aggressive variants of PTC were obtained for four markers: miRNA-146b, miRNA-221, fibronectin 1 (FN1), and cyclin-dependent kinase inhibitor 2A (CDKN2A) genes. A weak statistical correlation (0.0015 < p < 0.05) was observed for miRNA-31, -375, -551b, -148b, -125b, mtDNA, CITED1, TPO, HMGA2, CLU, NIS, SERPINA1, TFF3, and TMPRSS4. The recurrence risk of papillary thyroid carcinoma can be preoperatively predicted using miRNA-221, FN1, and CDKN2A genes.

AB - Molecular genetic events are among the numerous factors affecting the clinical course of papillary thyroid carcinoma (PTC). Recent studies have demonstrated that aberrant expression of miRNA, as well as different thyroid-related genes, correlate with the aggressive clinical course of PTC and unfavorable treatment outcomes, which opens up new avenues for using them in the personalization of the treatment strategy for patients with PTC. In the present work, our goal was to assess the applicability of molecular markers in the preoperative diagnosis of aggressive variants of papillary thyroid cancer. The molecular genetic profile (expression levels of 34 different markers and BRAF mutations) was studied for 108 cytology specimens collected by fine-needle aspiration biopsy in patients with PTC having different clinical manifestations. Statistically significant differences with adjustment for multiple comparisons (p < 0.0015) for clinically aggressive variants of PTC were obtained for four markers: miRNA-146b, miRNA-221, fibronectin 1 (FN1), and cyclin-dependent kinase inhibitor 2A (CDKN2A) genes. A weak statistical correlation (0.0015 < p < 0.05) was observed for miRNA-31, -375, -551b, -148b, -125b, mtDNA, CITED1, TPO, HMGA2, CLU, NIS, SERPINA1, TFF3, and TMPRSS4. The recurrence risk of papillary thyroid carcinoma can be preoperatively predicted using miRNA-221, FN1, and CDKN2A genes.

KW - CDKN2A

KW - FN1

KW - aggressive variants

KW - miRNA-146b

KW - miRNA-221

KW - papillary thyroid carcinoma

KW - recurrence risk

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85198452625&origin=inward&txGid=85759b37960caf5bb539fbc04d40600a

UR - https://www.mendeley.com/catalogue/f7ed0a71-32fb-3b07-958e-549430f764aa/

U2 - 10.3390/ijms25137090

DO - 10.3390/ijms25137090

M3 - Article

C2 - 39000197

VL - 25

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 13

M1 - 7090

ER -

ID: 60850658